We are live on ! Find out more
TTNP icon

Titan Pharmaceuticals

Delisted

TTNP was delisted on the 1st of October, 2025.

47 hedge funds and large institutions have $14.1M invested in Titan Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

18,367% more call options, than puts

Call options by funds: $1.11M | Put options by funds: $6K

219% more capital inflows, than outflows

Capital inflows: $3.6M | Capital outflows: $1.13M

175% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 4

2.6% more ownership

Funds ownership: 14.09% → 16.69% (+2.6%)

0% more funds holding

Funds holding: 47 → 47 (0)

13% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 8

Holders
47
Holders Change
–
Holders Change %
0%
% of All Funds
1.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
11
Reduced
4
Closed
8
Calls
$1.11​M
Puts
$6​K
Net Calls
+$1.1​M
Net Calls Change
+$45​K

TTNP Hedge Fund Activity: Q4 2016 in Review

47 of the 4,007 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q4 2016, worth a combined $14.1M — down 19% from $17.4M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of TTNP and 7 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 11 added.

The largest buyer was Morgan Stanley, adding an estimated $724K. The largest seller was AQR Capital Management, exiting entirely with an estimated $305K sold.

  • 47 institutional investors held Titan Pharmaceuticals (TTNP) as of Q4 2016, unchanged from Q3 2016.
  • Funds reported $14.1M of Titan Pharmaceuticals stock for Q4 2016, down 19% quarter-over-quarter.
  • 7 funds opened new Titan Pharmaceuticals positions in Q4 2016 and 8 closed out, a net change of -1 holder.
  • The largest Titan Pharmaceuticals buyer in Q4 2016 was Morgan Stanley, an estimated $724K added.
  • The largest Titan Pharmaceuticals seller in Q4 2016 was AQR Capital Management, an estimated $305K sold.

Based on aggregated 13F filings for Q4 2016.